EGFR and non-small cell lung carcinoma: Tyrosine kinase inhibitors (TKIs) of EGFR are regarded as the standard therapy regimen for NSCLC patients, and the first‐ and second‐generation TKIs have shown efficacy beyond that of platinum‐based chemotherapies for cancers with various mutations, including some with rare mutations.2, 3, 4, 5, 6